The Information Exchange Workgroup will make recommendations to the HIT Policy Committee on policies, guidance governance, sustainability, architectural, and implementation approaches to enable the exchange of health information and increase capacity for health information exchange over time.
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...jangeissler
A snapshot of EUPATI: Why the educated patient is so vital to success in clinical trials - Jan Geissler - EUPATI Director - presented at DIA EuroMeeting on 6 March 2013 in Amsterdam
The value off engaging patients in researchSimon Denegri
This is a talk I gave at the Council of Academic Hospitals of Ontario (CAHO) 'Healthier Wealthier, Smarter' conference in Toronto on 1st June 2015. Do visit their new website: http://caho-hospitals.com/
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...patvocates
Patient Advocates in Cancer Research: European Patients’ Perspective, presented by Jan Geissler (Twitter @jangeissler) at ISOQOL 19th Annual Conference, Budapast, 26 Oct 2012
The Information Exchange Workgroup will make recommendations to the HIT Policy Committee on policies, guidance governance, sustainability, architectural, and implementation approaches to enable the exchange of health information and increase capacity for health information exchange over time.
A snapshot of EUPATI: Why the educated patient is so vital to success in clin...jangeissler
A snapshot of EUPATI: Why the educated patient is so vital to success in clinical trials - Jan Geissler - EUPATI Director - presented at DIA EuroMeeting on 6 March 2013 in Amsterdam
The value off engaging patients in researchSimon Denegri
This is a talk I gave at the Council of Academic Hospitals of Ontario (CAHO) 'Healthier Wealthier, Smarter' conference in Toronto on 1st June 2015. Do visit their new website: http://caho-hospitals.com/
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...patvocates
Patient Advocates in Cancer Research: European Patients’ Perspective, presented by Jan Geissler (Twitter @jangeissler) at ISOQOL 19th Annual Conference, Budapast, 26 Oct 2012
The CMS Innovation Center hosted a Beneficiary Engagement and Incentives: Shared Decision Making (SDM) Model webinar regarding the model overview and Letter of Intent (LOI) process on Tuesday, January 10, 2017 from 2:00 - 3:00 p.m. EST. At this event, attendees learned more about the SDM model, eligibility criteria, and LOI requirements.
- - -
CMS Innovation Center
http://innovation.cms.gov
We accept comments in the spirit of our comment policy:
http://newmedia.hhs.gov/standards/comment_policy.html
CMS Privacy Policy
http://cms.gov/About-CMS/Agency-Information/Aboutwebsite/Privacy-Policy.html
c PJM6610 Foundations of Project Business Analysis.docxbartholomeocoombs
c
PJM6610 Foundations of Project Business Analysis
Prof. Johan Roos
Signature Assignment 1
Planning for Elicitation Assignment
Signature Assignment: Planning for Elicitation
By Group:
Mustafa Uzun, Shraddha Sherekar, Vikitha Veera
Content
1. An overview ……..………………….……………………………………………………………32. Elicitation plan ………………………………………..…………………………………………43. Project plan ……………………...…………….…………………………………………………54. References….…………………………………………………………………………………..…6
1. An Overview
Skype. It has a substantial market share (and mindshare), many people use it daily, yet nearly every core component of the program is seen as being out of date. The Skype corporation has been operating online for more than 20 years, and by spreading the word about its ability to make audio and video conversations via the internet instead of over the phone, it has grown its subscriber base.
Surveys, focus groups with observation, and floating questionnaires to clients who have used this product at least once are the finest ways to learn about the present status of the business and, consequently, the main product offering. It can be very helpful to identify the target audience and to provide useful inputs that could help define a future state for the product. Data obtained from online surveys through various e-commerce platforms with which the company has partnerships, data obtained from social media channels, and data from websites. Locals can provide insightful information that will serve as clear prompts for the company's R&D team as they plot the course for upcoming innovations or enhancements to current products.
Customer and influencer marketing-provided product evaluations are another crucial metric that may assist a business discover what consumers like and dislike about a product, as well as how they perceive its value, quality, and ability to effectively clean their teeth, among other things. The basic problem that the Skype team must overcome may be understood through root cause and opportunity analysis. Understanding the present situation of the product and the business may be accomplished with the use of this knowledge together with data from real surveys and website visitors.
2. Elicitation Plan
Elicitation Techniques:
1. Survey/Questionnaire
Stakeholders including end-users are presented with a series of questions over a survey or a questionnaire to help quantify their opinions. Following the gathering of the responses here, data is evaluated to determine the stakeholders' areas of focus that need improvement. High priority risks should be the basis for questions. Direct and clear questions are best. Closed-ended questions will help us focus on areas that we know need improvement while open-ended ones will help us comprehend what we may have overlooked.
Advantage:
The benefit of following this process is that data from a broad audience is simple to obtain and time taken to receive participants' re.
Presented by Goretti Gachagua, Eastern Africa Farmers Federation, at the FAO-ILRI Regional Training Workshop on Proven Livestock Technologies, ILRI, Addis Ababa, 3-5 December 2018
The issue of open-source models in the cost-effectiveness and disease-level (collaborative) models has been brewing for many years. There has been a marked growth in open science, and funding bodies and publishers increasingly require that research data be made available. As mentioned in our previous Issue Panel, “cost-effectiveness models synthesise a wide range of evidence to facilitate extrapolation over time and from intermediate to final decision endpoints. These models are often statistically sophisticated and require assumptions that are not directly testable. This can lead to decision-makers “discounting” the results of cost-effectiveness analyses, particularly if the developer is seen as partial.” Open-source models, then, would encourage greater transparency in pharmacoeconomic modeling and the reuse and updating of the best/most useful models; they are essential if cost-effectiveness analyses are to be widely accepted to reduce bias, increase transparency, improve model access, and allow for faster access to critical knowledge. The ISPOR-SMDM guidelines and the EUnetHTA joint action projects, are supportive of these views on collaboration, transparency, confidentiality, processes and consistency offered by the availability of open-source models to improve decision-making around health care and reimbursement. With openness and sharing, however, come issues of copyright and access and a need to define how model sharing can be achieved in a fair and equitable manner. There is, therefore, a need to develop an ongoing dialog on openness, especially where the research may be considered precompetitive and not worthy of IP investment. The pros and cons of open source models and the proposed mission of the Open Source Model SIG to curate an ongoing dialog regarding issues around creating, disseminating, sharing, evaluating, and updating open source cost-effectiveness and comparative effectiveness models will be debated amongst SIG members.
Author(s) and affiliation(s): Nancy Risebrough, Senior Principal, ICON plc, Toronto, Canada Jeroen P Jansen; Innovation & Value Initiative; Precision Medicine Group; and Stanford University Lotte Steuten, Vice President & Head of Consulting, Office of Health Economics, UK Renée JG Arnold, PharmD, RPh, ICON plc, New York, NY and Icahn School of Medicine at Mount Sinai, New York, NY, USA
Event: ISPOR 2019 Annual Meeting
Date: 20/05/2019
Efforts to place the patient at the center of medical research, spurred by the Affordable Care Act’s founding of the Patient Centered Outcomes Research Institute, have begun to change the way clinical research is conceptualized and conducted. Such efforts hold great promise, but also raise potential challenges for ethical oversight. How should oversight bodies approach the presence of patients in potentially unfamiliar research roles, such as investigator? What forms of patient involvement in research, if any, warrant increased scrutiny from oversight bodies? How do we keep the patient voice from being ‘captured’ by special interest groups? This symposium brought together a diverse group of patients and community members, policymakers, bioethicists, and regulatory officials to address these and other issues.
MGT 410Homework Set 1Provide a short answer to each of the fDioneWang844
MGT 410
Homework Set 1
Provide a short answer to each of the following questions.
1. Explain the difference between internal and external customers.
2. What might be some of the dangers of relying solely on customer input when designing or improving a product or service? What other inputs should be taken into account?
3. Compare and contrast Deming’s, Juran’s, and Crosby’s philosophies about quality.
4. What is the difference between quality control and quality assurance?
5. Discuss the differences between a dimension and a metric. How are they related? How do they differ?
6. Why is it important to assign weights to dimensions? What do the weights indicate?
7. How does a weighted dimension score differ from a raw dimension score?
8. What is the difference between the validity and reliability of a survey questionnaire?
9. How might an affinity diagram assist in content analysis?
10. Would “excellent product quality” be a strength for your firm if it was equivalent to the quality of competing products in the same market? Why or why not?
Exhibit 6.B: Elements of a Formally Structured Needs Assessment
Elements
Examples
Decide to conduct needs assessment
Make a conscious decision to complete a needs assessment with a commitment from key decision makers.
The Division of Continuing Medical Education, as part of the requirements for three major grant proposals, conducts a systematic statewide needs assessment of primary care physicians in a variety of settings.
Identify people and develop plan for needs assessment
Identify individuals to be involved in planning and overseeing the needs assessment, and develop a plan.
A steering committee of seven people is appointed, composed of two members of the Continuing Medical Education (CME) staff, two primary care physicians, a medical school faculty member, the assistant dean of the medical school, and an outside consultant. One of the CME staff is appointed as the project manager. The majority of the committee meetings are held online.
Determine context, purpose, and major questions
Determine important contextual factors, and develop purpose and major questions for the needs assessment.
The political and economic climate of the state, current trends in health care, and changes in the delivery of medicine constitute important contextual factors. The purpose for the needs assessment is to fulfill grant requirements for the proposals CME staff are preparing. With this context and purpose in mind the steering committee focuses the needs assessment on the following questions: (1) what are the major issues, needs, problems, and opportunities primary care physicians face in their practice?; and (2) in three years, how might these identified areas change, based on future forecasts and trends?
Determine logistics
Layout the target dates, time lines, budget, and staff.
The steering committee determines that it has to complete the needs assessment in six months. Two members of the CME staff ...
Consortium metrics discussion with IOM Drug ForumMark David Lim
Presentation made to the IOM Forum on Drug Discovery, Development, and Translation to explore the possibility of metrics that evaluate the performance of biomedical research consortia
CloseCareGap is an approved Patient Safety Organization (PSO). Using the award winning clinicalMessage ePlatform, staff can use smart tools to help measure best practice and reduce variations in care delivery at the bedside. The basic PSO toolkit is FREE and can be implemented with a few short clicks via a secure online portal. We have adopted the “IHI Leadership, Support and Care Processes” as critical areas to focus on closing gaps in care using a Continuous Learning Improvement Platform. For more information, go to http://www.clinicalmessage.org
Slide presentation for the June 4, 2014 joint PCORI/ National Institute on Aging (NIA) of the National Institutes of Health webinar. This webinar announced the selection of the research team that will carry out a major, five-year, $30 million patient-centered study of the effectiveness of individually tailored care plans to help older individuals avoid falls and related injuries.
The slide presentation that preceded of the annual Health Datapalooza in Washington DC, PCORI was pleased to participate in the latest installment in the Health Data Consortium and PricewaterhouseCoopers (PwC) Innovators in Health Data Series, a webinar featuring PCORI Executive Director Joe Selby, MD, MPH; NIH Director and PCORI Board of Governors member Francis Collins, MD, PhD; and Philip Bourne, PhD, NIH’s Associate Director for Data Science.
More Related Content
Similar to PCORI Advisory Panels Kickoff & Training
The CMS Innovation Center hosted a Beneficiary Engagement and Incentives: Shared Decision Making (SDM) Model webinar regarding the model overview and Letter of Intent (LOI) process on Tuesday, January 10, 2017 from 2:00 - 3:00 p.m. EST. At this event, attendees learned more about the SDM model, eligibility criteria, and LOI requirements.
- - -
CMS Innovation Center
http://innovation.cms.gov
We accept comments in the spirit of our comment policy:
http://newmedia.hhs.gov/standards/comment_policy.html
CMS Privacy Policy
http://cms.gov/About-CMS/Agency-Information/Aboutwebsite/Privacy-Policy.html
c PJM6610 Foundations of Project Business Analysis.docxbartholomeocoombs
c
PJM6610 Foundations of Project Business Analysis
Prof. Johan Roos
Signature Assignment 1
Planning for Elicitation Assignment
Signature Assignment: Planning for Elicitation
By Group:
Mustafa Uzun, Shraddha Sherekar, Vikitha Veera
Content
1. An overview ……..………………….……………………………………………………………32. Elicitation plan ………………………………………..…………………………………………43. Project plan ……………………...…………….…………………………………………………54. References….…………………………………………………………………………………..…6
1. An Overview
Skype. It has a substantial market share (and mindshare), many people use it daily, yet nearly every core component of the program is seen as being out of date. The Skype corporation has been operating online for more than 20 years, and by spreading the word about its ability to make audio and video conversations via the internet instead of over the phone, it has grown its subscriber base.
Surveys, focus groups with observation, and floating questionnaires to clients who have used this product at least once are the finest ways to learn about the present status of the business and, consequently, the main product offering. It can be very helpful to identify the target audience and to provide useful inputs that could help define a future state for the product. Data obtained from online surveys through various e-commerce platforms with which the company has partnerships, data obtained from social media channels, and data from websites. Locals can provide insightful information that will serve as clear prompts for the company's R&D team as they plot the course for upcoming innovations or enhancements to current products.
Customer and influencer marketing-provided product evaluations are another crucial metric that may assist a business discover what consumers like and dislike about a product, as well as how they perceive its value, quality, and ability to effectively clean their teeth, among other things. The basic problem that the Skype team must overcome may be understood through root cause and opportunity analysis. Understanding the present situation of the product and the business may be accomplished with the use of this knowledge together with data from real surveys and website visitors.
2. Elicitation Plan
Elicitation Techniques:
1. Survey/Questionnaire
Stakeholders including end-users are presented with a series of questions over a survey or a questionnaire to help quantify their opinions. Following the gathering of the responses here, data is evaluated to determine the stakeholders' areas of focus that need improvement. High priority risks should be the basis for questions. Direct and clear questions are best. Closed-ended questions will help us focus on areas that we know need improvement while open-ended ones will help us comprehend what we may have overlooked.
Advantage:
The benefit of following this process is that data from a broad audience is simple to obtain and time taken to receive participants' re.
Presented by Goretti Gachagua, Eastern Africa Farmers Federation, at the FAO-ILRI Regional Training Workshop on Proven Livestock Technologies, ILRI, Addis Ababa, 3-5 December 2018
The issue of open-source models in the cost-effectiveness and disease-level (collaborative) models has been brewing for many years. There has been a marked growth in open science, and funding bodies and publishers increasingly require that research data be made available. As mentioned in our previous Issue Panel, “cost-effectiveness models synthesise a wide range of evidence to facilitate extrapolation over time and from intermediate to final decision endpoints. These models are often statistically sophisticated and require assumptions that are not directly testable. This can lead to decision-makers “discounting” the results of cost-effectiveness analyses, particularly if the developer is seen as partial.” Open-source models, then, would encourage greater transparency in pharmacoeconomic modeling and the reuse and updating of the best/most useful models; they are essential if cost-effectiveness analyses are to be widely accepted to reduce bias, increase transparency, improve model access, and allow for faster access to critical knowledge. The ISPOR-SMDM guidelines and the EUnetHTA joint action projects, are supportive of these views on collaboration, transparency, confidentiality, processes and consistency offered by the availability of open-source models to improve decision-making around health care and reimbursement. With openness and sharing, however, come issues of copyright and access and a need to define how model sharing can be achieved in a fair and equitable manner. There is, therefore, a need to develop an ongoing dialog on openness, especially where the research may be considered precompetitive and not worthy of IP investment. The pros and cons of open source models and the proposed mission of the Open Source Model SIG to curate an ongoing dialog regarding issues around creating, disseminating, sharing, evaluating, and updating open source cost-effectiveness and comparative effectiveness models will be debated amongst SIG members.
Author(s) and affiliation(s): Nancy Risebrough, Senior Principal, ICON plc, Toronto, Canada Jeroen P Jansen; Innovation & Value Initiative; Precision Medicine Group; and Stanford University Lotte Steuten, Vice President & Head of Consulting, Office of Health Economics, UK Renée JG Arnold, PharmD, RPh, ICON plc, New York, NY and Icahn School of Medicine at Mount Sinai, New York, NY, USA
Event: ISPOR 2019 Annual Meeting
Date: 20/05/2019
Efforts to place the patient at the center of medical research, spurred by the Affordable Care Act’s founding of the Patient Centered Outcomes Research Institute, have begun to change the way clinical research is conceptualized and conducted. Such efforts hold great promise, but also raise potential challenges for ethical oversight. How should oversight bodies approach the presence of patients in potentially unfamiliar research roles, such as investigator? What forms of patient involvement in research, if any, warrant increased scrutiny from oversight bodies? How do we keep the patient voice from being ‘captured’ by special interest groups? This symposium brought together a diverse group of patients and community members, policymakers, bioethicists, and regulatory officials to address these and other issues.
MGT 410Homework Set 1Provide a short answer to each of the fDioneWang844
MGT 410
Homework Set 1
Provide a short answer to each of the following questions.
1. Explain the difference between internal and external customers.
2. What might be some of the dangers of relying solely on customer input when designing or improving a product or service? What other inputs should be taken into account?
3. Compare and contrast Deming’s, Juran’s, and Crosby’s philosophies about quality.
4. What is the difference between quality control and quality assurance?
5. Discuss the differences between a dimension and a metric. How are they related? How do they differ?
6. Why is it important to assign weights to dimensions? What do the weights indicate?
7. How does a weighted dimension score differ from a raw dimension score?
8. What is the difference between the validity and reliability of a survey questionnaire?
9. How might an affinity diagram assist in content analysis?
10. Would “excellent product quality” be a strength for your firm if it was equivalent to the quality of competing products in the same market? Why or why not?
Exhibit 6.B: Elements of a Formally Structured Needs Assessment
Elements
Examples
Decide to conduct needs assessment
Make a conscious decision to complete a needs assessment with a commitment from key decision makers.
The Division of Continuing Medical Education, as part of the requirements for three major grant proposals, conducts a systematic statewide needs assessment of primary care physicians in a variety of settings.
Identify people and develop plan for needs assessment
Identify individuals to be involved in planning and overseeing the needs assessment, and develop a plan.
A steering committee of seven people is appointed, composed of two members of the Continuing Medical Education (CME) staff, two primary care physicians, a medical school faculty member, the assistant dean of the medical school, and an outside consultant. One of the CME staff is appointed as the project manager. The majority of the committee meetings are held online.
Determine context, purpose, and major questions
Determine important contextual factors, and develop purpose and major questions for the needs assessment.
The political and economic climate of the state, current trends in health care, and changes in the delivery of medicine constitute important contextual factors. The purpose for the needs assessment is to fulfill grant requirements for the proposals CME staff are preparing. With this context and purpose in mind the steering committee focuses the needs assessment on the following questions: (1) what are the major issues, needs, problems, and opportunities primary care physicians face in their practice?; and (2) in three years, how might these identified areas change, based on future forecasts and trends?
Determine logistics
Layout the target dates, time lines, budget, and staff.
The steering committee determines that it has to complete the needs assessment in six months. Two members of the CME staff ...
Consortium metrics discussion with IOM Drug ForumMark David Lim
Presentation made to the IOM Forum on Drug Discovery, Development, and Translation to explore the possibility of metrics that evaluate the performance of biomedical research consortia
CloseCareGap is an approved Patient Safety Organization (PSO). Using the award winning clinicalMessage ePlatform, staff can use smart tools to help measure best practice and reduce variations in care delivery at the bedside. The basic PSO toolkit is FREE and can be implemented with a few short clicks via a secure online portal. We have adopted the “IHI Leadership, Support and Care Processes” as critical areas to focus on closing gaps in care using a Continuous Learning Improvement Platform. For more information, go to http://www.clinicalmessage.org
Slide presentation for the June 4, 2014 joint PCORI/ National Institute on Aging (NIA) of the National Institutes of Health webinar. This webinar announced the selection of the research team that will carry out a major, five-year, $30 million patient-centered study of the effectiveness of individually tailored care plans to help older individuals avoid falls and related injuries.
The slide presentation that preceded of the annual Health Datapalooza in Washington DC, PCORI was pleased to participate in the latest installment in the Health Data Consortium and PricewaterhouseCoopers (PwC) Innovators in Health Data Series, a webinar featuring PCORI Executive Director Joe Selby, MD, MPH; NIH Director and PCORI Board of Governors member Francis Collins, MD, PhD; and Philip Bourne, PhD, NIH’s Associate Director for Data Science.
The slide presentation from PCORI'S Advisory Panel on Assessment of Prevention, Diagnosis, and Treatment Options April 28-29, 2014 meeting in Alexandria, VA.
The slide presentation from the combined meeting of PCORI'S Advisory Panels on Patient Engagement and Addressing Disparities April 28, 2014 meeting in Alexandria, VA.
Slide presentation from Day Two of the PCORnet Partners meeting. The January 21-2, 2014 meeting took place at the Brookings Institute. This event launched the development of the nation’s most ambitious and promising clinical research network aimed at delivering high quality care through patient-centered outcomes research.
Slide presentation from Day One of the PCORnet Partners meeting. The January 21-2, 2014 meeting took place at the Brookings Institute. This event launched the development of the nation’s most ambitious and promising clinical research network aimed at delivering high quality care through patient-centered outcomes research.
Slide presentation from the October 30, 2013 webinar which described the process and rationale for PCORI’s unique approach to reviewing research proposals for funding.
Slide presentation from the November 13, 2013 webinar. This webinar was an opportunity to learn more about the Tier 1 Pipeline Awards, what type of projects PCORI is looking to fund, and how to apply.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
3. What is ExpertChoice?
3
ExpertChoice is a decision analysis software that is based
on multi-criteria decision making that uses mathematical
theory called analytic hierarchicial process
Created in 1983 by Thomas Saaty and Ernest Forman
Serves over 100 Fortune 500 companies such as IBM, used
by 30 Federal Agencies, and is taught in over 100
universities and used in 60 countries worldwide
4. Analytic Hierarchy Process
Information is broken into a hierarchy of
alternatives and criteria
Information is then synthesized to determine
relative ranking of alternatives
Both qualitative and quantitative information can be
compared using informed judgments to derive
weights and priorities
4
5. Hierarchical Tree Example
5
Style Reliability Fuel Economy
Selecting
a New Car
- Civic
- Saturn
- Prius
- Ferrari
- Civic
- Saturn
- Prius
- Ferrari
- Civic
- Saturn
- Prius
- Ferrari
• Hierarchy corresponds to
decision maker values
• No right answer
• Group decision must be
negotiated
7. Software for Ranking Activity:
Expert Choice
7
You’ll receive a personal link via e-mail which you will retrieve at
the time your panel decides to begin the ranking exercise
Please use Internet Explorer or Safari browsers if possible;
Mozilla Firefox is the best alternate
You will score each topic based on the 5 criteria described earlier,
using a 5 (high) to 1 (low) scale
18. When You Make it Through the Scoring..
18
These scores were inserted at random for training purposes
only and do not in any way reflect PCORI’s preference.
22. Expected Time Commitment
22
Online tools should be easy to use, each program
area has adopted a different approach for how and
when you will complete ranking exercises
Software experts will be floating throughout the day
After all panelists in your group have completed the
exercise, PCORI program staff will generate the
overall list for use in the discussion
23. Final Ranking
Discussion about important features of each
potential research topic will guide the ranking
All of the discussion is used as important input
We want to document the groups final ranking
using a consensus building approach
23
25. Link to Online Survey
25
Rank your list: from 1 (your first choice topic) to 5
(or more—depending on how many topics your
group decides—for your lowest)
Your group facilitator will provide the link and final
number of topics
27. Thank You for Your Time and Support of
This Important Process
27
28. Q&A Session
Anne Beal, MD, MPH
Deputy Executive Director, Chief Operating Officer and
Chief Officer for Engagement, PCORI
Advisory Panel Kickoff and Training
April 19, 2013
1
29. Wrap-Up and
Announcements
Anne Beal, MD, MPH
Deputy Executive Director, Chief Operating Officer and
Chief Officer for Engagement, PCORI
Advisory Panel Kickoff and Training
April 19, 2013
2
30. Agenda
! The remainder of the event will take place in
breakout sessions by panel
! Room Assignments:
Advisory Panel on Addressing Disparities (Hickory)
Advisory Panel on Improving Healthcare Systems (Chestnut)
Advisory Panel on Assessment of Prevention, Diagnosis, and
Treatment Options (Poplar)
Advisory Panel on Patient Engagement (Walnut)
3
31. Consent Notice
! Please keep in mind that the breakout sessions
will be recorded and open to the public
4
32. Administrative Items
Please note that the COI form will be disclosed on our website
! Complete and submit the following forms at the registration desk:
Audio/Visual Release Form
PCORI Conflict of Interest (COI) Form
! Panelist will receive a $1,500 stipend, and Chairpersons will
receive $2,000 stipend
! Complete all forms for payment. Finance team members are
located in the Dogwood room (downstairs)
5
Payment Schedule
May 2013 October 2013
$750 $750 Panelist
$1,250 Chair
33. Appointing Panel Chairpersons
The chairperson may assemble subcommittees composed of
members to examine special issues and facilitate activities
related to the scope of work in a panel’s charter.
! Nominations and self nominations may be submitted to
advisorypanels@pcori.org by 5:00 PM (ET) Monday, April 22
! Identify the name of the nominee, panel, and rationale in one
brief paragraph no longer than 500 words
! Staff will review nominations and make recommendations
! The PCORI Board of Governors will select a chairperson to
facilitate panel activities in conjunction with PCORI’s designated
staff leader
6
34. Future Meetings
! Advisory Panels will convene no more than four times a
year, with the option of monthly conference calls
! The Chairperson will play a key role in scheduling
future meetings
! Program Directors will discuss future meeting dates
during the breakout sessions
! Proposed dates for face-to-face meetings:
September 20–21, 2013
December 6–7, 2013
March 14–15, 2014
7
35. Advisory Panel Group Photographs
! We will be taking group photos of each Advisory
Panel
Immediately after this session (12:00 PM):
• Advisory Panel on Improving Healthcare Systems
• Advisory Panel on Assessment of Prevention, Diagnosis, and Treatment Options
After lunch (12:50 PM):
• Advisory Panel on Patient Engagement
• Advisory Panel on Addressing Disparities
8
38. PCORI’s Mission
! Affordable Care Act (ACA) 2010 says PCORI shall
fund research that:
Discovers new information
Allows patients/families/clinicians and health system
leaders to make better decisions between alternative
approaches
Leads to better patient-centered outcomes of care
2
39. Engagement
! The ACA also says that PCORI’s research must be
conducted by scientists who are engaged with
patients and stakeholders (such as clinicians,
executives of provider organizations, administrators
of insurance companies, and representatives of
manufacturers)
! Significant engagement extends throughout the
research process
3
40. National Priorities for Research and
Research Agenda
• Comparisons of alternative clinical options to support personalized decision making and self-care
• Identifying patient differences in response to therapy
• Studies of patient preferences for various outcomes
• Improving support of patient self-management
• Focusing on coordination of care for complex conditions and improving access to care
• Comparing alternative strategies for workforce deployment
• Understanding and enhancing shared decision making
• Alternative strategies for dissemination of evidence
• Exploring opportunities to improve patient health literacy
• Understanding differences in effectiveness across groups
• Understanding differences in preferences across groups
• Reducing disparities through use of findings from PCOR
• Improving study designs and analytic methods of PCOR
• Building and improving clinical data networks
• Methods for training researchers and patients to participate in PCOR
• Establishing methodology for the study of rare diseases
4
41. What Is a Healthcare System?
! Through the patient’s lens—all the providers of the care
I receive, as well as my insurer
! Through the provider’s lens—all the providers with
whom I interact, as well as the insurers
! Through the insurer’s lens—all the providers I pay to
care for my insured lives
! Through the economist’s lens—all the patients,
providers, and insurers in a geographic area
! Through your lens?
5
42. How Can Healthcare Systems Be
Improved?
! Changes in the deployment of personnel
! Changes in the use of information
! Changes in operating policies
! Changes in patients’ behaviors
! Changes in payment policies
! Changes in linkages to community agencies
! Other changes?
6
43. Vision
PCORI’s IHS program will produce new
scientific information to:
! Transform the quality and efficiency of
critical components of the US healthcare
system
! Improve health-related outcomes that
matter most to Americans
7
44. How Can Patients Benefit?
! Processes—Engagement in self-care, coordination
of care, improved access to care, better quality of
care
! Outcomes—Improved quality of life, greater
satisfaction with care, greater functionality in life
roles
8
47. IHS Method
! PCORI’s IHS program enters into contracts under
which selected organizations perform specified
health systems–related research, and PCORI pays
them an agreed amount
11
48. The Roles of Patients and Stakeholders on
Research Teams
Engaged patients and stakeholders:
Participate in the formulation of
the research questions to be answered
Help define essential characteristics
of study participants, the comparators,
and the outcomes to be measured
Help monitor the conduct and the
progress of the study
Help disseminate the study’s results
12
49. Patient-Centered Outcomes
! Patient-centered outcomes (PCOs) are outcomes
people care about, for example:
Symptoms
Unwanted events
Health
Quality of life
Function
Safety
Survival
13
50. What Kinds of Features Should Be Studied?
! Deployment of personnel
! Information technology (IT)
! Incentives
! Special programs, such as navigators who link
medical care to community services that promote
patient self-management
! Others?
14
52. Outline for Our Topic Brief Discussion
! Primary discussant(s) briefly describes the topic to
orient the panel ~2 minutes
! Secondary discussant(s) can add any other
information ~1 minute
16
54. Rating Topics Using Criteria
18
Highest (Meets criteria)
Lowest (Does not meet criteria)
55. Criteria for Research Prioritization
! Patient-centeredness
Is the research of specific interest to patients and caregivers?
! Impact of the condition on individual/population health
Prevalence, incidence, morbidity, productivity, mortality
! Options for addressing the issue
What could new research contribute toward patient-centered
outcomes?
! Likelihood of implementing research results into
practice
How likely are study findings to change clinical practice?
! Durability of information
How long will the information resulting from this research be
valuable?
19
56. #1 Compared to usual care, what are the effects of
accountable care organization care on patient-centered
outcomes among patients with chronic conditions?
20
Introduction: • The accountable care organization (ACO) model is patient-centered, with
quality measures falling into four domains outlined by CMS: patient
experience, care coordination and patient safety, preventive health services,
and attention to at-risk populations
• ACOs are designed to change practice patterns by aligning incentives
Burden: • Chronic conditions affect >50% of US population
• Accounts for >75% of healthcare spending
• Seven out of 10 deaths in the US are related to chronic disease
• Prevalence of chronic conditions in younger people has increased
• Chronic conditions account for disability and diminution in quality of life
Options for
addressing issue:
• ACOs
• There are no guidelines or systematic reviews that address the impact of
ACOs on patient-centered outcomes (PCOs)
• The steps each is taking to implement an accountable care model are varied
Potential for new
information to
improve care and
PCOs rapidly:
• Identifying best practices for assigning patients to ACOs
• Developing measures to assess ACOs with respect to PCOs
• Creating a taxonomy of implementation strategies and critically assessing the
merits of each
57. #2 What are the relative effects of different models of chronic care on
PCOs?
21
Introduction: • Much of the occurrence and many of the complications of chronic diseases
are also preventable
• Failures of the disease management approach have led to an increased focus
on patient-centered management, which includes individualized treatment
Burden: • Chronic conditions affect >50% of US population
• Account for >75% of healthcare spending
• Seven out of 10 deaths in the US are related to chronic disease
• Prevalence of chronic conditions in younger people has increased
• Chronic conditions account for disability and diminution in quality of life
Options for
addressing issue:
• Traditional medical model: disease management focusing on single condition
• Newer models have focused on individual patients and their multiple needs
• Outcomes that extend beyond clinical outcomes
• A multidisciplinary team that extends beyond medical care
Potential for new
information to
improve care and
PCOs rapidly:
• Identifying best models and the relative effects of those models on PCOs
• Identifying which models maximize PCOs in various patient groups
• Identifying elements of a model that make it more or less successful
• Identifying the appropriate PCOs being evaluated
• Target model selection to the correct patients to maximize PCOs
58. #3 Compared to usual care, what is the effect of care management
(designed to optimize care coordination and continuity) on PCOs
among patients with COPD?
22
Introduction: • COPD includes chronic bronchitis and emphysema
• Patients have diverse needs arising from the disease itself
• Practice guidelines offer little guidance for these patients with complex and
variable needs
Burden: • >12 million Americans affected
• Fourth leading cause of morbidity and mortality in the United States
• Direct cost estimated to be $30 billion in United States and indirect $20 billion
• Evidence shows practitioners adhere poorly to guideline recommendations
Options for
addressing
issue:
• >40 guidelines released in last five years focusing on diagnostic strategies
and treatment recommendations
• The failure of traditional approaches suggests the need for management
strategies that are patient-centered and include individualized treatment
Potential for new
information to
improve care and
PCOs rapidly:
• Benefits of specialists, co-management, or referral for different patient groups
• Structure of provider teams
• How to structure care management in solo or small practices
• Care management to reduce ED usage, hospitalizations, and readmissions
59. #4 Compared to usual care, what is the effect of care management
(designed to optimize care coordination and continuity) on PCOs
among patients with cancer?
23
Introduction: • Common approach is based in clinical practice guidelines, focusing on
diagnostic criteria and treatment recommendations
• Treatment must also manage the patient’s individual needs arising from
associated comorbidities and treatment complications
Burden: • Cancer affects >1 million Americans
• Cancer is the second leading cause of mortality in the United States
• Direct costs of cancer were $124 billion in 2010
• Incidence rates have remained stable or risen slightly in the last 10 years
Options for
addressing issue:
• Hundreds of cancer guidelines have been issued in the last five years,
focusing on diagnosis and treatment
• Guidelines on screening and early diagnosis exist for some cancers; however,
adherence is low
• Survivorship care plans exist to address the needs of cancer survivors, but
lack evidence on whether they improve patient outcomes
Potential for new
information to
improve care and
PCOs rapidly:
• Impact of new developments in diagnostics and treatment on patients
• How to facilitate the transition to life after cancer
• Little research has been done on fear of recurrence
60. #5 Compared to usual care, what is the effect of care management
(designed to optimize care coordination and continuity) on PCOs
among patients requiring palliative care?
24
Introduction: • Palliative care is patient- and family-centered care with the goal of optimizing
quality of life, by focusing on pain and symptom management, communication
about goals and care planning, and psychosocial and spiritual support
• PCOs may extend to family-caregiver–centered outcomes
Burden: • Despite the benefits, hospice care usually does not occur in the United States
• As much as 1/3 of healthcare utilization occurs at the end of life
• Disparities exist related to race and income in areas such as pain
management, communication, and use of hospice care
Options for
addressing
issue:
• Care management is one type of palliative care intervention
• Moderate evidence for the effectiveness of palliative care interventions, but
results vary depending on the outcomes, population, and settings
• Limited evidence for other types of interventions, such as advance care
planning, quality improvement, and policy initiatives
Potential for new
information to
improve care and
PCOs rapidly:
• Larger, more inclusive, better quality studies that include a comprehensive
range of patient populations, types of conditions, and outcomes to target and
prioritize outcomes, increase access to care, and reduce disparities
• Impact of improving communication about goals and care planning in settings
other than intensive care units
61. #6 Compared to usual care, what is the effect of care management
(designed to optimize care coordination and continuity) on PCOs
among pregnant women?
25
Introduction: • Care management models include expanding the scope of prenatal care
beyond prevention of adverse outcomes to include emphasis on quality of
care, continuity of care, maternal education, and social support
• These models generally rely on the addition of nurses and other trained
personnel to the care team
Burden: • Maternal mortality has increased in recent years (13 deaths/100,000 births)
• Adverse infant outcomes may lead to long-term health consequences and
may pose a financial and emotional burden to caregivers
Options for
addressing issue:
• Standard care: aims to optimize medical outcomes by providing regular
screening and medical care
• Care management: seeks greater continuity, more communication, and more
pregnancy education, while minimizing delays in screening and treatment
• Care management models are generally individual to institutions and difficult
to generalize
Potential for new
information to
improve care and
PCOs rapidly:
• Determine the impact of care management on clinical and patient-centered
outcomes
• Identify which models deliver the best outcomes
• Determine whether care management helps with the early identification and
care for high-risk pregnancies
62. #7 Compared to usual care, what is the effect of care management
(designed to optimize care coordination and continuity) on PCOs
among patients with multiple chronic conditions?
26
Introduction: • Patients with two or more chronic conditions are said to have multimorbidity or
multiple chronic conditions (MCCs)
Burden: • 75 million people have MCCs
• MCC patients are more likely to take multiple medications, have a higher rate
of adverse events, more psychological distress, more rates of disability, and
poorer quality of life than the rest of the population
Options for
addressing
issue:
• There are no standard management options for people with MCCs
• Application of multiple single-condition clinical practice guidelines (common,
but not optimal)
• Individualized treatment plans, focused on the patient and his or her needs,
with the patient an active participant in his or her own care
• Effects of care management on PCOs for MCCs are not well understood
Potential for new
information to
improve care and
PCOs rapidly:
• Optimal mix of providers structure of the teams providing care management
• Optimal frequencies and modalities of interaction with care management team
• Which PCOs should be targeted for improvement with care management
• Determining whether approaches to care management need to be modified
based on the intended outcomes
64. #8 Compared to care management provided by insurance companies,
what is the effect of care management provided by medical homes on
PCOs among patients with MCCs?
28
Introduction: • Care management includes coordination of care and educational activities to
help people with chronic conditions understand their condition and to achieve
optimal health and quality of life
Burden: • 75 million people have MCCs
• Patients with MCCs are more likely to take multiple medications, have a
higher rate of adverse events, more psychological distress, more rates of
disability, and poorer quality of life than the rest of the population
Options for
addressing issue:
• Patient-centered medical homes (PCMHs): provide care management with a
primary care physician as the leader of patient care and care coordination
activities
• Care management by insurance companies: utilizes non-physician personnel,
generally offsite, to coordinate care
• Insufficient evidence to compare clinical outcomes of care coordination in
patients with MCCs in medical homes versus insurance companies
Potential for new
information to
improve care and
PCOs rapidly:
• Effect of PCMHs on PCOs for patients with MCCs
• Implementation methods for PCMHs
• Identifying elements that have significant effect on outcomes on patients with
MCCs
65. #9 Compared to usual care, what is the effect of care from a non-
physician PCMH on care quality and PCOs?
29
Introduction: • PCMHs may be directed and staffed by providers other than physicians, such
as physician assistants (PAs), nurse practitioners (NPs), nurses, or other
specially trained staff
Burden: • ~1/3 of current physicians practice primary care, but only 1/4 of current
medical school graduates plan on careers in primary care
• Within 10 years, the deficit of primary care physicians will be 40,000
Options for
addressing
issue:
• The American College of Family Physicians has stated that PAs should be
recognized as primary care providers in the PCMH model
• There is speculation that NPs could also fulfill roles as primary care providers
• No published trials have evaluated PCMHs led by PAs, NPs, nurses, or other
non-physicians
Potential for new
information to
improve care and
PCOs rapidly:
• Evaluate the effectiveness of PCMHs led and staffed by PAs and NPs on care
quality and PCOs
• Identify elements required for rapid uptake of this model
66. #10 Compared to primary care alone, what is the effect of primary
care co-located with mental health services on mental health
symptoms, medication use, and other PCOs?
30
Introduction: • WHO recommends integrating mental health care with primary care services
and the promotion of mental health along with general health
Burden: • Half of all Americans will develop some mental illness in their lifetime
• 17% of US adults have both a physical and mental health condition
• Mental illness is associated with diminished well-being, unhealthy behaviors,
and reduced overall quality of life
• Health disparities tend to be exacerbated for mental health care due to access
and other social factors
Options for
addressing
issue:
• Collaborative care: includes mental health services in the primary care setting
• Some evidence for improvement on specific outcomes, such as the mental
condition itself, patient satisfaction, and quality of life
• Lacking evidence on outcomes such as medication adherence, self-
management, symptom burden, and clinical outcomes relevant to the medical
condition
Potential for new
information to
improve care and
PCOs rapidly:
• Comparison of different models: treatment by primary care physician, co-
managed, or referred
• Identifying the effect on a comprehensive range of patient outcomes
• Optimal structure of provider teams
• Identifying whether mental health disease also increases risk for other
medical problems
67. #11 Compared to direct transportation to a regional trauma center,
what is the effect of stabilization at a local hospital (followed by
transfer to a regional trauma center) on survival and other PCOs?
31
Introduction: • A trauma center is a hospital that has resources and equipment needed to
care for severely injured patients
• Local hospitals can provide initial assessment and treatment of trauma but are
not designated as trauma centers if they do not have trauma surgeons and
other necessary hospital resources
Burden: • Injuries are the leading cause of death for children and adults ages 1 to 44
• Nearly one in five (45 million) Americans live in regions without access to a
Level I or II trauma center within one hour of where they are injured
Options for
addressing
issue:
• Trauma systems: includes both trauma centers and non-trauma centers for
the care of injured individuals in a region
• Inclusive system: all hospitals within a region participate in the trauma system
• Exclusive system: all injured patients are preferentially sent to the few trauma
centers
Potential for new
information to
improve care and
PCOs rapidly:
• Optimal triage and management of patients within trauma systems
• Effect of different triage models on PCOs
68. #12 Compared to usual care, what is the effect of information
technology (e.g., EHRs, PHRs, and decision support) on providers’
compliance with guidelines and chronically ill patients’ adherence to
treatment plans?
32
Introduction: • Clinical decision support (CDS) systems enhance compliance to clinical
practice guidelines (CPGs) by providers and increase adherence to treatment
by patients
• ACA provides large incentives for adoption of CDS-enabled electronic health
records (EHRs) and provides patient health records (PHRs) to patients
Burden: • <50% of Americans receive the recommended treatment based on CPGs
• Due to poor communication across systems and providers, patients with
chronic conditions, especially those with multiple conditions, are at risk of
having duplicated tests and more adverse events
Options for
addressing issue:
• Health information technology (HIT) solutions (e.g., EHRs and PHRs) that are
CDS-linked
• Patient-focused guidelines directly implemented in the PHR
Potential for new
information to
improve care and
PCOs rapidly:
• New HIT tools (e.g., CDS)
• Strategies for implementing CDS-linked HIT systems
• Proper application of CPGs in planning a treatment while considering patient-
centered preferences and outcomes
• Effect of HIT tools on provider compliance and patient adherence
69. #13 What are the relative effects of different quality improvement
strategies on the quality of preventive services, acute care, chronic
care, and rehabilitative services—and on PCOs—for adults and
children?
33
Introduction: • According to the Institute of Medicine, high-quality care is care that is safe,
effective, patient-centered, timely, efficient, and equitable
• Applications of quality improvement (QI) have spanned all components of
care, including preventive, acute, chronic, and rehabilitative services
Burden: • ~1/2 of patients receive suboptimal or unsatisfactory care
• An estimated 1/3 of total healthcare expenditures in the United States
represent waste
• Deficiencies in the quality of care lead to excess morbidity and mortality
Options for
addressing issue:
• Good evidence for QI strategies to address preventive and chronic care
• Some evidence for a variety of different multimodal interventions for specific
acute conditions in different contexts
• Insufficient data for strategies for QI efforts for rehabilitative services
Potential for new
information to
improve care and
PCOs rapidly:
• Research on the effectiveness of QI for acute and rehabilitative care
• Rigorous evaluation of QI efforts (e.g., using randomized designs,
comprehensive outcomes, and generalizable populations)
• Implementation strategies (including developing local leadership and capacity
for management and measurement)
70. #14 What are the relative effects of different insurance features (e.g.,
benefit designs, utilization management, cost sharing) on chronically
ill patients’ access to care, quality of care, and PCOs?
34
Introduction: • Fee-for-service payment models are often costly for both the insurer and the
patient, and they can reward the provision of unnecessary care
• Recently, new insurance options have been developed, and their benefits and
risks for the chronically ill remain to be seen
Burden: • Chronic conditions affect >50% of US population
• Accounts for >75% of healthcare spending
• Nearly 2/3 of Medicare beneficiaries have two or more chronic conditions
• Copays and premiums are often unaffordable for chronically ill individuals,
and medical bills contribute importantly to personal debt and bankruptcy
Options for
addressing issue:
• Alternatives to fee-for-service insurance designs
• Value-based insurance design: co-payment inversely related to proven benefit
• “Consumer-directed health plan”: offers financial incentive for consumers to
become involved in purchasing decisions for their own health care
• Little evidence for these plans on access, quality, and outcomes
Potential for new
information to
improve care and
PCOs rapidly:
• Determine whether different insurance features reduce payments for medical
services while preserving the health of their beneficiaries
• Experiment through voluntary participation in alternative designs in Medicare,
Medicaid, and private insurance
• Effect of different designs on access, quality, and PCOs
71. #15 Compared to usual care, what are the effects of different models
of transitional care on patient safety and other PCOs?
35
Introduction: • Transitional care: strategies designed to ensure the coordination and
continuity of health care as patients transfer between different locations or
different levels of care
Burden: • Transitioning from inpatient to outpatient care, as well as transitioning to
higher intensity care, are both periods of increased risk for adverse events
• ~20% of patients have adverse events after discharge, half of which are
considered preventable
• Deficiencies in transitional care are felt largely through costs due to hospital
readmissions
Options for
addressing issue:
• Transitional care involves three basic elements to guarantee continuity of care
and quality: communication, medication reconciliation, and education
• The evidence to support these interventions is fairly robust
Potential for new
information to
improve care and
PCOs rapidly:
• How to best implement evidence-based transitional care strategies in real-
world settings
• Effective tools and processes to improve transitions
• Effect of different models and tools on outcomes
74. Principles to Guide Us: Patients asked for
Transparency, Efficiency, Collaboration
Transforming Patient-
Centered Research:
Building Partnerships
and Promising Models
Washington DC,
October 27-28, 2012
75. Engaging the Wider Community
! A two-pronged approach to identify high-priority
research questions
Investigator-initiated Approach
Patient- and Other Stakeholder-initiated Approach
3
76. Patient- and Other Stakeholder-Initiated Approach
PCORI receives research topics from patients and other stakeholders
Advisory Panels prioritize research topics based on explicit criteria
PCORI issues specific funding announcements for
highest priority topics
Peer review prioritizes
applications by level
of alignment
with criteria
Diverse research portfolio answering key
questions for patients, clinicians, and
healthcare leaders
Researchers and stakeholders develop
responsive applications
80. Topic Generation
Creating Funding Announcements
Gap
Confirmation
Research
Opportunities
8
Research
Prioritization
Research
Prioritization
Final Selection
for Specific PFAs
82. PCORI is Building on the Existing Evidence
Base and Prior Experience
10
Existing Scientific
Work and Literature
Methodology
Committee and
Methodology Report
Experience of
Other Agencies
Federal Coordinating
Council for
Comparative
Effectiveness
Research
84. 1. Patient-Centeredness
12
• Are patients and clinicians
asking for this research ?
• Will research findings make a
difference to patients and
their clinicians when making
healthcare decisions ?
85. 2. Impact
13
• Burden of disease in terms
of prevalence, mortality,
morbidity, individual suffering,
loss of productivity?
• Rare disease?
86. 3. Options for Addressing the Issue
14
• What is known about the relative
benefits and harms of the
available management options?
• What could new research
contribute?
• Have recent innovations (eg, a
new technology or a new policy)
made research on this topic
especially compelling?
87. 4. Likelihood of Implementation in Practice
15
• How likely is it that the
research findings will be
implemented in
practice?
88. 5. Duration of Information
16
• Will research findings be
valid by the time the study
has concluded?
89. Piloting the Process
17
• Piloted from August to November
2012
• 35 Pilot participants
• 8 criteria to prioritize 10 topics
• Results
• Feedback
90. Questions to Pilot from a Diverse Range of
Disease Areas
Obesity
Back Pain
in the Elderly
Indoor
Air
Pollution
Falls in
the
elderly
Prostate
Cancer
Anti-
psychotics
in Young
Adults
Breast
Cancer
Coronary Artery
Disease
Clostridium
Difficile
18
92. Group 1 Results Using Two
Software Programs
0.00%2.00%4.00%6.00%8.00%10.00%12.00%
Indoor air pollution
interventions
Effectivenss of multiple
chronic conditions
Mindfulness-based
interventions and
obesity
Treatment for C. difficile
diarrhea
Efficacy of
antipsychotics in
adolescents and
Prevention of falls in the
elderly
Management of elderly
patients with back pain
Treatment of ductal
carcinoma in situ (DCIS)
Biomarkers for the
prevention of breast
cancer
Treatment of coronary
artery disease
7.30%
8.79%
9.55%
9.64%
9.99%
10.20%
10.52%
11.03%
11.21%
11.77%
Expert Choice Survey Gizmo
67
137
145
145
152
156
177
199
201
216
0 50 100 150 200 250
Indoor Air Pollution
Obesity
Preventing Falls
Multiple Chronic Conditions
Antipsychotics in ADHD,
bipolar disorder or
schizophrenia
Diarrheal Infection Clostridium
Difficile
Treatment of Ductal Carcinoma
In Situ
Management of Back Pain in
Elderly Patients
Biomarkers for Breast-Cancer
Coronary Artery Disease
Total Score
93. Group 2 Results
21
0.00% 2.00% 4.00% 6.00% 8.00% 10.00% 12.00%
Indoor air pollution interventions
Treatment for C. difficile diarrhea
Effectivenss of multiple chronic conditions
Efficacy of antipsychotics in adolescents and children
Mindfulness-based interventions and obesity
Management of elderly patients with back pain
Biomarkers for the prevention of breast cancer
Prevention of falls in the elderly
Treatment of coronary artery disease
Treatment of ductal carcinoma in situ (DCIS)
7.28%
9.07%
9.49%
9.53%
9.89%
9.94%
10.69%
10.74%
11.41%
11.96%
94. Participants Provided Valuable Insights to
Improve the Process
22
Emphasize
Patient’s
Voice
Clarify the
Criteria
Improve
Supporting
Information
Choose the
Tools
95. Research Topics Submitted this Cycle
! 1393 topics submitted
552 topics excluded
841 topics accepted
23
Research Topics
Accepted
Excluded
96. Source of Accepted Topics
ANA= American Nurses Association
ANCC is the American Nurses Credentialing Center
24
AHRQ
25%
ANA and ANCC
3%
Friends of Cancer
2%
IOM
11%
NIH
8%
Web
39%
Stakeholder
Workshop
12%
97. Prioritizing Research Topics
APDTO
594
1393 Research Topics
841 Accepted Topics
552 Excluded Topics
20 Topics 15 Topics 12 Topics
Reviewed in
future cycle
IHS
308
AD
47
CD
97
98. Steps in Ranking Research Topics
Learn how to use the tool Expert
Choice
Review and discuss topic briefs
Do ranking exercise
Discuss results and conduct final
ranking
PCORI Staff will commission
landscape reviews (Summer
2013) and present their
recommendations to the Board
(September 2013).
Funding expected Q1 2014.
26
99. Expectations of Advisory Panel
Participants
! Challenge
! Experience
! Honoring others’ contributions
! Respectful dissonance
! Feedback to PCORI about
process and improvements!
27
102. Program Introduction and Overview
1 pm – 1:30 pm
David Hickam, MD, MPH
Program Director
Assessment of Prevention, Diagnosis, and
Treatment Options
PCORI
2
103. Advisory Panel Topic Selection Process
3
1. Public Input: PCORI received 1,393
research questions via the Web. 594 related to
Assessment of Options.
2. Topic Selection: PCORI staff selected 20
topics in the Assessment of Options category
(see Orientation guide).
3. Panel Review: 20 topic briefs inform
prioritization based on PCORI research
criteria.
4. Board Approval: high-priority topics will be
considered for funding announcements from
PCORI.
Score
Discuss
Rank
Goal: Generate a list of five prioritized topics.
104. Discussion of Topic Briefs
1:30 pm – 3:30 pm
4
Format (12 minutes per topic)
1. Background (3-5 minutes)
• What is the important clinical question?
• What are the gaps in current research?
• Could research close these gaps?
2. Discussion (7-10 minutes)
• Does the topic meet the 5 PCORI criteria?
106. Discussion of Topic Briefs - continued
3:45 pm – 5:45 pm
6
Format (12 minutes per topic)
1. Background (3-5 minutes)
• What is the important clinical question?
• What are the gaps in current research?
• Could research close these gaps?
2. Discussion (7-10 minutes)
• Does the topic meet the 5 PCORI criteria?
108. Recap of Day 1: Address
Questions or Concerns
8 AM
8
109. Discussion of Topic Briefs: Review Tabled Items
8:15 am – 9:15 am
9
Format
1. Background
• What is the important clinical question?
• What are the gaps in current research?
• Could research close these gaps?
2. Discussion
• Does the topic meet the 5 PCORI criteria?
110. Ranking of All Topics
9:15 am – 10 am
10
• Expert Choice
• Objectives are the PCORI criteria
• Alternatives are the short topic
titles
• Scoring: 5 (high) – 1 (low)
119. Welcome and Overview
of the Advisory Panels
Joe Selby, MD, MPH
Executive Director, PCORI
Advisory Panel Kickoff & Training
April 19, 2013
1
120. Source: Affordable Care Act. Subtitle D—Patient-Centered Outcomes Research.
PUBLIC LAW 111–148—MAR. 23, 2010.
“The purpose of the Institute is to assist
patients, clinicians, purchasers, and policy-
makers in making informed health
decisions by advancing the quality and
relevance of evidence concerning the manner
in which diseases, disorders, and other health
conditions can effectively and appropriately be
prevented, diagnosed, treated, monitored, and
managed through research and evidence
synthesis that considers variations in patient
subpopulations and the dissemination of
research findings with respect to the relative
health outcomes, clinical effectiveness, and
appropriateness of medical treatments,
services.
Purpose
Of
PCORI
PCORI’s Broad Mandate
121. Welcome to PCORI
! PCORI funds research intended to provide patients
and those who care for them the information they
need to make better-informed healthcare decisions.
! Our core duties are to:
Establish national research priorities
Establish and carry out a research agenda
Develop and update methodological standards
Disseminate research findings
3
122. Why PCORI is Necessary
BMJ – Clinical Evidence 2013
123. Continuum of Medical Research
Basic
Science
Clinical
Research
Effectiveness
Research
T1
RCTs for Efficacy
and Safety
T2
Implementation/
Effectiveness
studies
Molecular discovery
Etiologic and
mechanistic
research
PCOR
Comparative
Outcomes
Studies
125. PCORI Funding – Approximate
2012
2013
2014
2015
....
2019
$150,000,000*
$300,000,000
$500,000,000
$500,000,000
$500,000,000
* 20% each year goes to AHRQ/HHS 7
126. PCORI’s Key Criteria for Funding
8
! Potential for Improvement – How likely is the
proposed research to lead to changes in patient or
clinician practices that lead in turn to meaningful
improvement in patient health?
! Patient-Centeredness – Is the proposed research
focused on comparisons and outcomes that matter to
patients and their caregivers?
! Patient and Stakeholder Engagement – Have the
researchers included in their team relevant patients and
other key healthcare community members,
representative of those who would use its information?
127. Our First Topics for Targeted Research Funding
! Jump-starts our long-term effort
to identify and prioritize specific
research topics to study
! Leverages stakeholder input
! Ad hoc workgroup meetings
recorded and available on the
PCORI Web site
Research Topics:
Treatment Options for Severe Asthma in
African-American and Hispanic/Latino
populations
Treatment Options for Uterine Fibroids
Preventing Injuries from Falls in the Elderly
Treatment Options for Back Pain
Obesity Treatment in Diverse Populations
9
128. Long-term Approach to Targeted Research:
PCORI Advisory Panels
10
! PCORI established the first four Advisory
Panels in March 2013
! 1,295 applications were reviewed by PCORI
staff, and the final panel slates were approved
by the Board of Governors
! Each panel has 21 members consisting of
patients, researchers, clinicians, and other
experts with relevant experience and
knowledge to inform PCORI’s work
! Each panel has a unique charter, term duration,
and clearly defined scope of work
Addressing
Disparities
Assessment of
Prevention,
Diagnosis, and
Treatment
Options
Improving
Healthcare
Systems
Patient
Engagement
129. Overview of PCORI Advisory Panels
11
What does the law say about advisory panels?
Legislative
Authorization
• PCORI can appoint permanent or ad hoc advisory panels to assist in identifying research
priorities and establishing the research project agenda.
• Advisory panelists will include representatives of practicing and research clinicians, patients,
and experts in scientific and health services research, health services delivery, and evidence-
based medicine who have experience in the relevant topic, and as appropriate, experts in
integrative health and primary prevention strategies.
What’s the purpose of advisory panels?
Purpose
• Advisory panelists work in conjunction with PCORI staff to help identify research priorities and
topics
• Leveraging members’ expertise will help better inform PCORI’s mission and work.
130. Will panel members be eligible for future PCORI funding?
Conflicts of Interest
• Panel members are not making decisions on either funding or funding announcements.
• PCORI will maintain “firewalls” between Advisory Panel members and internal decisions that
would convey any knowledge advantage to panel members.
• Advisory panel meetings are recorded and publicly available immediately after a meeting.
• Therefore, membership generally does not preclude eligibility for funding.
What has been approved by PCORI’s Board?
Panel Charters
• Charters and panel slates were reviewed and approved for four panels: Assessment of
Prevention, Diagnosis, and Treatment Options; Addressing Disparities; Improving
Healthcare Systems; and Patient Engagement.
• Members will initially be appointed for a one-year term, with the possibility of reappointment for
a maximum of two terms.
• Term of the charter will remain in effect for one year beginning on the day of the first meeting.
• Charter is subject to review, reauthorization, amendment, or termination by the Board of
Governors or its designee.
Overview of PCORI Advisory Panels
12
131. PCORI’s Board of Governors
13
PCORI Board of Governors, March 2012 in Baltimore, MD
132. Why PCORI Needs You
! Advisory Panels will assist PCORI in developing and refining our
patient-centered comparative clinical effectiveness research portfolio
and in disseminating research findings through:
prioritization of proposed research topics
provision of input and expertise on questions that arise within the Advisory
Panel’s focus area
periodic evaluation of PCORI’s research portfolio
Ongoing two-way communication with stakeholder communities
Ensuring the highest patient engagement standards and a culture of patient-
centeredness in both our work and the research that we fund.
14
133. Distribution of Advisory Panelists
15
20%
41%
18% 21%
Panelists by Stakeholder Group
(Self-Identified; N=84)
* Map of census regions and divisions of the United States made available by the U.S. Census
Bureau, U.S. Department of Commerce, Economics and Statistics Administration.
Panelists by Geographic Location
(Self-Identified; N=84)
134. General Session Agenda
16
Time Session PCORI Presenters
8:45-9:15 Welcome and Overview of the Advisory Panels Joe Selby, Executive Director
9:15-9:35 Patient Engagement in Research Sue Sheridan, Director, Patient
Engagement
9:35-10 Q&A Session Anne Beal, Deputy Executive
Director & Chief Officer for
Engagement
10:15-11:15 Research Prioritization Training Rachael Fleurence, Acting
Director, PCOR Methods
11:15-11:45 Software Training Kara Odom Walker, Program
Officer
11:45-12 Wrap-Up and Announcements Anne Beal, Deputy Executive
Director & Chief Officer for
Engagement
135. Patient Engagement in Research
Susan Sheridan, MBA, MIM
Director, Patient Engagement
Advisory Panel Kickoff & Training
April 19, 2012
136. How PCORI Engages Patients in Research
! Identifying and Selecting Research Questions
! Reviewing Research Proposals for Funding
! Conducting PCORI-Funded Research
! Matching Patients and Stakeholders with
Researchers
! Disseminating Research to the Community
! Evaluating PCORI’s Patient and Stakeholder
Engagement Programs
137. Transforming Patient-Centered Research:
Building Partnerships and Promising Models
! PCORI’s October 2012 workshop included five breakout sessions to
help PCORI implement a patient-centered research agenda through
sustained and meaningful engagement.
! PATIENT ENGAGEMENT WORKSHOP VIDEO
138. Identifying and Selecting Research
Questions
! How should PCORI identify and select specific research
questions for funding that are patient-centered?
139. Identifying and Selecting Research
Questions
PCORI Web
site
Roundtables
Workshops
PCORI
Methodology
Report
Advisory
Panels
140. Reviewing Research Proposals for Funding
! How can PCORI effectively engage and use the real-world
experience of patients to help evaluate research proposals
we receive?
141. Reviewing Research Proposals for Funding
! Building a community of informed stakeholder
reviewers
Training patients and stakeholders on PCORI review
criteria, process, and instructions on how to
score PCORI Funding Applications
Identifying Reviewer Mentors
Matching expertise with research priority area
Equalizing voices at the reviewer table
142. Conducting PCORI-Funded Research
! PCORI Methodology Report
Standards Associated with Patient-Centeredness
! Review of PCORI Funding Applications
Patient-Centeredness
! Exemplary models of patient engagement in
research
High Plains Research Network - Boot Camp Translation
for Patient-Centered Outcomes (Dr. Westfall & Maret
Felzien)
143. Matching Patients and Stakeholders with
Researchers
! How can PCORI connect patients and stakeholders with
researchers for collaborative work that ensures studies
reflect patient perspectives?
145. Matching Patients and Stakeholders with
Researchers
! The PCORI Challenge Initiative
Developing a patient/research “matching” system that
will effectively connect potential partners interested in
seeking funding from us for rigorous patient-centered
outcomes research
146. Disseminating Research to the Community
! How do we ensure that patients and those who care for
them can access and use PCORI’s research to make more-
informed decisions?
147. Disseminating Research to the Community
! Speeding the implementation of and use of PCOR
! Becoming a trusted resource for information
! Engaging stakeholders from across the healthcare
community to include PCORI research in training,
practice, and standards
148. Evaluating PCORI Engagement Activities
! How can PCORI measure the effectiveness of its programs
to involve patients and stakeholders throughout its work?
149. Evaluating PCORI Engagement Activities
! Maximizing engagement activities to inform
programs and understand the impact
! Building trust in PCORI through transparent
communication of the results of engagement efforts
150. Introduction & Overview
of Patient Engagement
Sue Sheridan, MBA, MIM
Director, Patient Engagement
Advisory Panel Kickoff & Training
April 19, 2013
1
151. Who are we as a group?
Stakeholder Group #
Patient, Caregiver & Patient Advocate 13
Researcher 2
Clinician, Physician 2
Clinician, Occupational Therapist 1
Clinician, Nurse 1
Industry, Pharmaceuticals 1
Policymaker 1
2
152. What brings you here?
Please introduce yourself to the group:
Name
Where are you from?
Why did you decide to support PCORI’s work in this
area?
3
153. Questions to Consider
Creating a community – what is the role of this
advisory panel?
What is true patient-centeredness?
What does success look like?
What is your experience?
4
154. Agenda for Today
5
Session Objective
Introductions & Patient
Engagement Overview
Panelist introductions
Patient Engagement Advisory
Panel Charge & Work Plan
Share meeting objectives and overall vision for the panel
Facilitate the development of a vision document
Write the panel scope of work together
Brainstorming
Begin considering PCORI-pedia (notecards are available for
idea sharing)
Share pre-meeting activity responses
The Roles of Patients in
Research
Share and discuss what is meaningful patient engagement in
research
Matching Patients and
Stakeholders with Researchers
Share and discuss best practices in matching patients and
researchers
Evaluation of Engagement Efforts
Current evaluation strategies
The potential role the panel could play in this capacity moving
forward
155. Advisory Panel on
Patient Engagement
Charge & Work plan
Sue Sheridan, MBA, MIM
Director, Patient Engagement
Advisory Panel Kickoff & Training
April 19, 2013
6
156. Source: Affordable Care Act. Subtitle D—Patient-Centered Outcomes Research.
PUBLIC LAW 111–148—MAR. 23, 2010.
“The purpose of the Institute is to assist
patients, clinicians, purchasers, and policy-
makers in making informed health
decisions by advancing the quality and
relevance of evidence concerning the manner
in which diseases, disorders, and other health
conditions can effectively and appropriately be
prevented, diagnosed, treated, monitored, and
managed through research and evidence
synthesis that considers variations in patient
subpopulations and the dissemination of
research findings with respect to the relative
health outcomes, clinical effectiveness, and
appropriateness of medical treatments,
services.
Purpose
Of
PCORI
PCORI’s Broad Mandate
157. Advisory Panel on Patient Engagement
Charge
Advise on processes to identify research topics and
priorities that are important to patients;
Advise on all aspects of stakeholder review of
applications for PCORI funding;
Provide general recommendations to PCORI and externally
on the conduct of patient-centered research;
Advise on methods to evaluate the impact of patient
engagement in research;
Assist and advise PCORI on communications, outreach,
and dissemination of research findings; and
Provide advice on other questions and areas of interest that
may arise that are relevant to PCORI’s mission and work.
8
158. Meeting Objectives
Familiarize panelists with PCORI’s mission, national
priorities, and the purpose and function of the Advisory
Panels
Inform panelists on all of PCORI’s engagement
opportunities
Train panelists in research prioritization
Review recommendations on best practices in patient
engagement in research outlined in the final workshop
report and offer additional input
Receive advice and recommendations on the Engagement
Awards and Ambassadors Program
Collaboratively develop a pledge for the panel, as well as a
work plan and expectations of panelists for Year 1
9
159. Meeting Outputs
Patient Engagement Panel vision document
Patient Engagement Panel work plan
Edits to PCORI Ambassadors Program and the
Engagement Awards
Recommendations and enhancements for best
practices in patient engagement in research
PCORI-pedia – definitions for PCORI terms
10
160. Advisory Panel on Patient Engagement
Work Plan
Identify goals to work toward over the next 12
months
11
162. Review Responses to Pre-Meeting Activity
What is the biggest hope I have for patient-
centered research?
What does success look like for patient
engagement in PCORI's research?
13
163. Idea Capture
This is an opportunity to share any additional
ideas, hopes, and goals you may have for the
Patient Engagement Advisory Panel
14
164. The Roles of Patients in
Research
Sue Sheridan, MBA, MIM
Director, Patient Engagement
Advisory Panel Kickoff & Training
April 19, 2013
15
166. The Roles of Patients in Research
What is meaningful patient engagement in
research?
17
167. Matching Patients and
Stakeholders with
Researchers
Sue Sheridan, MBA, MIM
Director, Patient Engagement
Advisory Panel Kickoff & Training
April 19, 2013
18
168. Methodology Standards Associated with
Patient-Centeredness
PC-1 Engage people representing the population of
interest and other relevant stakeholders in ways that are
appropriate and necessary in a given research context.
Stakeholders can be engaged in the processes of:
Formulating research questions;
Defining essential characteristics of study participants, comparators, and
outcomes;
Identifying and selecting outcomes that the population of interest notices
and cares about (eg, survival, function, symptoms, health-related quality
of life) and that inform decision making relevant to the research topic;
Monitoring study conduct and progress; and
Designing/suggesting plans for dissemination and implementation
activities.
19
170. Review Criterion 7: Team and Environment
(Current)
Are the investigators appropriately trained and experienced to carry out
the planned studies?
Is the work proposed appropriate to the experience level of the principal
investigator?
Does the study team have complementary and integrated expertise?
Is their leadership approach, governance, and organizational structure
appropriate for the project?
Are relevant patients and other key
stakeholders of the study information
appropriately involved in the design and
implementation of the study?
Do the experiments proposed take advantage of unique features of the
scientific environment or employ useful collaborative arrangements?
Is there evidence of institutional or other support?
The 8 Merit Review Criteria:
1. Impact of the Condition
2. Innovation/Potential for
Improvement
3. Impact on Healthcare
Performance
4. Patient-Centeredness
5. Rigorous Research Methods
6. Inclusiveness of Different
Populations
7. Team and Environment
8. Efficient Use of Resources
21
172. Challenge Background
PCORI is committed to meaningful patient,
caregiver, and stakeholder engagement as a tool
for rigorous research.
PCORI funding announcements require that
patients be fully engaged throughout research
process.
Engagement is among the criteria PCORI uses to
score applications.
23
173. The Challenge
Develop a “matching” system that can connect
researchers and potential patient partners.
Solution could be:
A well-articulated conceptual model.
An adaptation of existing matching protocol.
A prototype or an entirely new Web-based service or
app.
Some combination of these approaches, or something
else entirely.
24
174. The Challenge
Two first-place awards:
Conceptual model – $10,000
Prototype of app – $40,000
Winners’ work may be considered for additional
PCORI support, depending on outcome of the
review process.
Submission materials: slide deck (5 slides),
overview doc (5 pgs), video demo (5 min), link to
working app (optional)
25
175. Evaluation Criteria
Technical feasibility, usability, and scalability of the
proposed conceptual model/prototype.
Differences in ways patients, caregivers, and
researchers understand, describe and seek
answers to problems or issues they face.
Maximizing patient-centeredness and scientific
rigor.
Particular challenges of serving hard-to-reach
audiences: ethnic and racial minorities, rural
populations, the elderly, physically challenged
people, and non-English speakers.
26
176. Timeline
Submission period began: December 14, 2012
Submission period ended: April 15, 2013
Winners notified: May 15, 2013
Winners announced: at a major national health
conference in the spring of 2013
27
179. Vision for Engagement Research
Evaluation is fundamental to understanding and
improving all that PCORI does.
Engagement Research ensures that PCORI
understands and maximizes the impact of its
research funding to help people make informed
healthcare decisions and improve healthcare delivery
and outcomes.
30
180. Goals for Engagement Research
Evaluate research engagement by PCORI awardees
to identify and support best practice
Evaluate impact of PCORI funding
Establish a survey research function to inform PCORI
programs
Evaluate PCORI engagement and outreach
programs
31
181. Elements for Evaluation of Research
Engagement from PCORI Workshop
Define success
Determine goals of engagement by research phase
Establish feedback channels
Address patient and researcher parity
Assess patient and researcher perceptions of the
value and appropriateness of engagement
32